Understand the source comparison
PE-22-28 Safe Side Effects: Full Comparison
PE-22-28 Mild GI discomfort (12–18%), headache (6–9%), transient insomnia None observed at ≤5mg/kg α7 nAChR-selective, minimal muscarinic activity 0.5–2.5mg/kg SC Strong preclinical safety profile with minimal off-target effects. Suitable for extended research
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- PE-22-28
- Mild GI discomfort (12–18%), headache (6–9%), transient insomnia
- None observed at ≤5mg/kg
- α7 nAChR-selective, minimal muscarinic activity
- 0.5–2.5mg/kg SC
- Strong preclinical safety profile with minimal off-target effects. Suitable for extended research protocols with standard monitoring
- Noopept
- Irritability (8–14%), insomnia (10%), headache (7%)
- Mild hepatic enzyme elevation (5% incidence)
- Non-selective cholinergic, glutamate modulation
- 10–30mg oral
- Broader receptor activity increases variability in response. More common CNS-related side effects
- Semax
- Nasal irritation (22% intranasal), anxiety (4–6%)
- None at standard doses
- Melanocortin receptor modulation, BDNF upregulation
- 0.3–1mg intranasal
- Safe but route-dependent side effects. Subcutaneous administration reduces incidence
- Dihexa
- Potential hepatotoxicity at doses >5mg/kg, limited human data
- Hepatic changes observed in high-dose animal studies
- HGF/c-Met pathway agonist
- 0.5–2mg/kg oral
- Promising cognitive effects but incomplete long-term toxicology data. Requires hepatic monitoring